PMID- 10073943
OWN - NLM
STAT- MEDLINE
DCOM- 19990401
LR  - 20211203
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 283
IP  - 5408
DP  - 1999 Mar 12
TI  - HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
PG  - 1748-52
AB  - A selective advantage against infectious disease associated with increased 
      heterozygosity at the human major histocompatibility complex [human leukocyte 
      antigen (HLA) class I and class II] is believed to play a major role in 
      maintaining the extraordinary allelic diversity of these genes. Maximum HLA 
      heterozygosity of class I loci (A, B, and C) delayed acquired immunodeficiency 
      syndrome (AIDS) onset among patients infected with human immunodeficiency 
      virus-type 1 (HIV-1), whereas individuals who were homozygous for one or more 
      loci progressed rapidly to AIDS and death. The HLA class I alleles B*35 and Cw*04 
      were consistently associated with rapid development of AIDS-defining conditions 
      in Caucasians. The extended survival of 28 to 40 percent of HIV-1-infected 
      Caucasian patients who avoided AIDS for ten or more years can be attributed to 
      their being fully heterozygous at HLA class I loci, to their lacking the 
      AIDS-associated alleles B*35 and Cw*04, or to both.
FAU - Carrington, M
AU  - Carrington M
AD  - Intramural Research Support Program, Science Applications International 
      Corporation Frederick, National Cancer Institute (NCI), Frederick, MD 21702-1201, 
      USA.
FAU - Nelson, G W
AU  - Nelson GW
FAU - Martin, M P
AU  - Martin MP
FAU - Kissner, T
AU  - Kissner T
FAU - Vlahov, D
AU  - Vlahov D
FAU - Goedert, J J
AU  - Goedert JJ
FAU - Kaslow, R
AU  - Kaslow R
FAU - Buchbinder, S
AU  - Buchbinder S
FAU - Hoots, K
AU  - Hoots K
FAU - O'Brien, S J
AU  - O'Brien SJ
LA  - eng
GR  - N01-CO-56000/CO/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
SB  - IM
CIN - Science. 1999 Jul 2;285(5424):11
MH  - Acquired Immunodeficiency Syndrome/genetics/*immunology
MH  - Adult
MH  - Alleles
MH  - Antigen Presentation
MH  - Cohort Studies
MH  - Disease Progression
MH  - Ethnicity
MH  - *Genes, MHC Class I
MH  - Genetic Predisposition to Disease
MH  - HIV Infections/genetics/*immunology
MH  - HIV Long-Term Survivors/statistics & numerical data
MH  - *HIV-1
MH  - HLA Antigens/genetics
MH  - HLA-B Antigens/*genetics
MH  - HLA-C Antigens/*genetics
MH  - Heterozygote
MH  - Homozygote
MH  - Humans
MH  - Killer Cells, Natural/immunology
MH  - Loss of Heterozygosity
MH  - Proportional Hazards Models
MH  - Risk
EDAT- 1999/03/12 00:00
MHDA- 1999/03/12 00:01
CRDT- 1999/03/12 00:00
PHST- 1999/03/12 00:00 [pubmed]
PHST- 1999/03/12 00:01 [medline]
PHST- 1999/03/12 00:00 [entrez]
AID - 10.1126/science.283.5408.1748 [doi]
PST - ppublish
SO  - Science. 1999 Mar 12;283(5408):1748-52. doi: 10.1126/science.283.5408.1748.